Tianyi Medical Completes Two Cross-border Acquisitions Totaling RMB 5 Billion to Expand Global CRRT Portfolio

▲March 6-7New Drug Innovators SummitScan to register

Note:This article does not constitute any investment opinions or recommendations.The official/company announcement shall prevail; this article only introduces drugs related to medical health, not a recommendation of treatment plans (if involved), and does not represent the platform's position. Any article reprint requires authorization.

PharmRingLearned: Recently, TIANYIMED (301097.SZ) successfully acquired the global CRRT (Continuous Renal Replacement Therapy) business of Japan's Nikkiso Co., Ltd. in collaboration with its actual controller.

TIANYIMED is a leading enterprise in the field of blood purification in China, with a strong R&D foundation and significant brand influence in the polymer medical device sector. It has been listed as a national-level specialized and innovative "little giant" enterprise recommended for support. Its business covers countries and regions in Asia, Europe, and the Americas, maintaining good business cooperation relationships with international hemodialysis leaders such as Fresenius Medical Care and Baxter Healthcare. Meanwhile, TIANYIMED is also the first medical device company in China to obtain a registration certificate for CRRT-specific tubing. Relying on advanced and mature R&D technology and an experienced management team, TIANYIMED focuses on the field of blood purification, continuously developing high value-added products, gradually upgrading its product structure, accelerating its global layout, and enhancing its overall competitiveness.

The counterparty of this transaction, Nikkiso Co., Ltd., is a well-known Japanese manufacturer of hemodialysis equipment and is also a publicly listed company on the Tokyo Stock Exchange in Japan. Nikkiso's medical device business provides hemodialysis solutions worldwide, and its hemodialysis devices have significant brand influence and a certain market share in global markets. The investment amount for this transactionApproximately 400 millionYuan.

The listed company previously stated: There is a strong synergistic effect with the target assets. In the future, TIANYIMED will integrate and standardize the target business, and choose the right time to incorporate the target assets into the listed company system. This cross-border acquisition is a milestone event in TIANYIMED's global layout, laying a solid foundation for its future global development.

Moreover: On February 15, 2025, TIANYIMED issued an announcement regarding its external investment. The company plans to acquire the CRRT (Continuous Renal Replacement Therapy) - filter business assets of BELLCO S.R.L. ("BELLCO"), a subsidiary of Medtronic, through its wholly-owned Singaporean subsidiary PRIMACRON GLOBAL PTE.LTD., in a cash transaction. The consideration for the transaction is expected to be 11.99 million euros / approximately the total investment amount.Approximately 100 million yuanRMB; The operating entity of the underlying asset is located in Italy, and the formal signing has been completed.

As of the closing on February 18, the company's market value was approximately 2.2 billion RMB.

Attachment Sharing: SendCross-border Acquisition(Please copy correctly) to the followingPharmaCircleThe original file of the company's transaction announcement can be obtained from the WeChat Official Account backend. For learning, communication, and sharing purposes only!

Reference:

NMPA/CDE；

Moxie Pharma Data pharma.bcpmdata.com (formerly known as Yirong Cloud Data);

FDA/EMA/PMDA；

Relevant companies have publicly disclosed (all images in the text are from the official enterprises unless otherwise stated);

https://www.tianyi-med.com/；

https://mp.weixin.qq.com/s/H2wgIrGH9UiWXOeLRJSYSg；

https://data.eastmoney.com/notices/stock/301097.html；

https://data.eastmoney.com/notices/detail/301097/AN202502141643094044.html; etc.

This article is intended to provide scientific information to healthcare professionals only, and does not represent the platform's position, nor does it recommend any medication or product. For more pharmaceutical company information exchange, please leave a business card in the backstage.

The schedule is subject to the actual event.